Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Feb 26, 2015
Sangamo BioSciences Presents New Clinical Data at CROI 2015 From Trial of ZFP Therapeutic® Designed to Provide Functional Control of HIV

Feb 25, 2015
Sangamo BioSciences Announces Presentation At The Cowen And Company 35th Annual Health Care Conference


View all »Events & Presentations

Mar 4, 2015 at 8:40 AM ET
Cowen and Company 35th Annual Health Care Conference

Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
17.98
Change:
+ 0.90
Day High:
18.14
Day Low:
16.70
Volume:
1,295,800
4:00 PM ET on Mar 4, 2015

Shareholder Tools